Watch for Vir's ability to deliver preclinical candidates and trigger the near-term $45M milestone payments. The $25M equity investment at a 30% premium to the $14.16/share price provides a floor and signals Gilead's conviction. Monitor for IND filings and clinical data readouts on the TCE candidates.
Price Chart
Executive Summary
Vir Biotechnology entered into a collaboration and license agreement with Gilead Sciences to discover and engineer three novel PRO-XTEN dual-masked T-cell engager (TCE) development candidates for solid tumors. Concurrently, Gilead agreed to purchase 1,765,486 shares of Vir common stock at $14.16 per share for approximately $25 million. The deal provides Vir with $90 million in upfront consideration ($65M cash + $25M equity at a 30% premium), up to $45 million in near-term preclinical milestones, and up to $1.74 billion in further development, regulatory, and commercial milestones plus royalties.
Key Financial Metrics
Key Facts
- Gilead Sciences to purchase 1,765,486 shares of Vir common stock at $14.16 per share for ~$25 million
- Upfront consideration of $90 million ($65M cash + $25M equity investment at a 30% premium)
- Up to $45 million in potential near-term preclinical milestone payments
- Up to $1.74 billion in further development, regulatory and commercial milestones
- Tiered high single-digit to low double-digit royalties on net sales
- Collaboration targets three novel PRO-XTEN dual-masked T-cell engager (TCE) development candidates for solid tumors
- Gilead receives exclusive license to develop and commercialize the novel TCEs
- Standstill, voting, and lockup provisions expire one year after closing of the SPA
Financial Impact
Up to $135 million in total upfront and near-term preclinical milestone payments, plus up to $1.74 billion in further milestones and tiered royalties
Risk Factors
- Preclinical TCE candidates may fail to advance into clinical development
- Dilution from 1,765,486 new shares (~1.8% of shares outstanding based on typical float)
- Collaboration execution risk with a large pharma partner
- No guarantee of milestone achievement or eventual commercialization
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001628280-26-065826 |
| Document: a2026-10x14_8xkxplatinumxp.htm | 0001628280-26-065826 |
| Document: 0001628280-26-065826-index-headers.html | 0001628280-26-065826 |
| Document: 0001628280-26-065826-index.html | 0001628280-26-065826 |
| Document: 0001628280-26-065826.txt | 0001628280-26-065826 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 14, 2026 12d ago | 8-K | $10.41 $10.57 | ▲ +1.54% | ▲ +1.08% | $11.04 (+6.05%) |
Oct 8, 2026 18d ago | 8-K | $11.12 $10.47 | ▼ −5.85% | ▼ −5.57% | $11.04 (−0.72%) |
Oct 6, 2026 20d ago | 3 | $11.60 $10.61 | ▼ −8.53% | ▼ −8.40% | $11.04 (−4.83%) |
Oct 1, 2026 25d ago | 8-K | $11.29 $11.12 | ▼ −1.51% | ▼ −2.81% | $11.04 (−2.21%) |
Sep 23, 2026 4w ago | Court Ruling | $10.72 $11.29 | ▲ +5.32% | ▲ +5.73% | $11.04 (+2.99%) |
Aug 14, 2026 10w ago | Court Ruling | $9.39 $9.91 | ▲ +5.54% | ▲ +6.73% | $11.04 (+17.57%) |
Aug 9, 2026 11w ago | Institutional Cluster | $8.89 $9.39 | ▲ +5.62% | ▲ +5.67% | $11.04 (+24.18%) |
Jul 24, 2026 13w ago | 8-K | $8.69 $8.90 | ▲ +2.42% | ▲ +2.04% | $11.04 (+27.04%) |
Jun 29, 2026 17w ago | 144 | $10.38 $10.02 | ▼ −3.47% | ▼ −4.86% | $11.04 (+6.36%) |
Jun 10, 2026 19w ago | 3 | $8.52 $9.30 | ▲ +9.15% | ▲ +8.72% | $11.04 (+29.58%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers